MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ISCO had $46K increase in cash & cash equivalents over the period. $46K in free cash flow.

Cash Flow Overview

Change in Cash
$46K
Free Cash flow
$46K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
57 -127
Stock-based compensation
63 161
Depreciation and amortization
56 109
Non-cash operating lease expense
79 150
Interest expense on related party note payable
35 75
Change in inventory reserve
-26 55
Accounts receivable
-86 43
Inventories
-12 470
Prepaid expenses and other current assets
-107 146
Accounts payable
-132 211
Accrued liabilities
-199 124
Operating lease liabilities
-89 -172
Net cash (used in) provided by operating activities
49 -73
Purchases of property and equipment
3 37
Net cash used in investing activities
-3 -37
Payments on related party note payable
0 200
Net cash used in financing activities
0 -200
Net decrease in cash
46 -310
Cash and cash equivalents at beginning of period
1,230 -
Cash and cash equivalents at end of period
966 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

International Stem Cell CORP (ISCO)

International Stem Cell CORP (ISCO)